riz rouge fermenté + co-enzyme Q10
Food supplement declared in France, declaration No 2018-5-382, decision dated 16 May 2018
riz rouge fermenté + co-enzyme Q10, from BVBA MANNAVITA, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Monascus purpureus 800 mg per day, Ubiquinone. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- BVBA MANNAVITA
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Kidney failure, Kidney disease, Infants (under 1 year), Liver problems
Declaration 155073, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Monascus purpureus Went | Graine | Autre extrait sec | 800 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Ubiquinone | not declared |
Additives
E460, E464, E470b, E471, E551
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Ne convient pas aux femmes enceintes ou allaitantes, aux enfants et adolescents, aux personnes de plus de 70 ans, aux personnes ayant des problèmes hépatiques, rénaux ou musculaires, aux personnes prenant des médicaments qui peuvent donner lieu à des interactions (ex : hypocholestérolémiants), aux personnes intolérantes aux statines. En cas de doute, veuillez demander conseil à votre médecin ou à votre pharmacien.
Regulatory points
- Conditions légales
Contains red yeast rice. Monacolins must remain below 3 mg per daily portion, with mandatory warnings on the label. The monacolin content is not declared in Compl'Alim.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/860).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Riz Rouge Fermenté + Co-enzyme Q10 Mannavital, declared in 2024 : different composition: 0 ingredient(s) added, 1 missing
- Riz Rouge Fermenté + Co-enzyme Q10 Mannavital, declared in 2024 : different composition: 3 ingredient(s) added, 3 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “riz rouge fermenté + co-enzyme Q10: composition and regulation”, https://compoatlas.com/en/supplements/products/155073-riz-rouge-fermente-co-enzyme-q10, updated 15 November 2026.